Cargando…

Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients

SIMPLE SUMMARY: Cost-effective, Hepatocellular carcinoma (HCC) risk-based surveillance strategies should be established after achieving sustained virologic response (SVR). Circulating microRNAs are considered stable serum markers for early cancer diagnosis and prognosis and treatment response predic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsai, Yi-Shan, Huang, Ching-I, Tsai, Pei-Chien, Yeh, Ming-Lun, Huang, Chung-Feng, Hsieh, Meng-Hsuan, Liu, Ta-Wei, Lin, Yi-Hung, Liang, Po-Cheng, Lin, Zu-Yau, Chen, Shinn-Cherng, Huang, Jee-Fu, Chuang, Wan-Long, Dai, Chia-Yen, Yu, Ming-Lung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030777/ https://www.ncbi.nlm.nih.gov/pubmed/35454929 http://dx.doi.org/10.3390/cancers14082023

Ejemplares similares

Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C
por: Tsai, Yi-Shan, et al.
Publicado: (2020)

Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy
por: Huang, Chung-Feng, et al.
Publicado: (2016)

Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study
por: Huang, Chung-Feng, et al.
Publicado: (2019)

Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment
por: Huang, Chung-Feng, et al.
Publicado: (2016)

Tolloid-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals
por: Huang, Chung-Feng, et al.
Publicado: (2018)

Corrigendum to “Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment” [EBioMedicine 15 (2017) 81–89]
por: Huang, Chung-Feng, et al.
Publicado: (2017)

Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C: A Nationwide Survey in Taiwan
por: Yu, Ming-Lung, et al.
Publicado: (2015)

Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy
por: Lu, Ming-Ying, et al.
Publicado: (2016)

The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C
por: Batsaikhan, Batbold, et al.
Publicado: (2018)

Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C
por: Yeh, Ming-Lun, et al.
Publicado: (2018)

Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database
por: Tsai, Pei-Chien, et al.
Publicado: (2017)

Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes
por: Huang, Ching-I, et al.
Publicado: (2018)

The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma
por: Yeh, Ming-Lun, et al.
Publicado: (2017)

Association of hyperuricemia with disease severity in chronic hepatitis C patients
por: Jang, Tyng-Yuan, et al.
Publicado: (2018)

Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals
por: Lin, Chuan-Pin, et al.
Publicado: (2021)

Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
por: Hsu, Po-Yao, et al.
Publicado: (2021)

Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C
por: Huang, Chung-Feng, et al.
Publicado: (2017)

Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C
por: Lu, Ming-Ying, et al.
Publicado: (2016)

Pegylated-Interferon Alpha Therapy for Treatment-Experienced Chronic Hepatitis B Patients
por: Yeh, Ming-Lun, et al.
Publicado: (2015)

Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan
por: Tsai, Pei-Chien, et al.
Publicado: (2021)

Virological Predictors of Response to Retreatment in Hepatitis C Genotype 2 Infected Patients
por: Huang, Chung-Feng, et al.
Publicado: (2013)

The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis
por: Jang, Tyng-Yuan, et al.
Publicado: (2019)

Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues
por: Jang, Tyng-Yuan, et al.
Publicado: (2021)

Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication
por: Lu, Ming-Ying, et al.
Publicado: (2022)

Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients
por: Yeh, Ming-Lun, et al.
Publicado: (2019)

Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease
por: Huang, Jee-Fu, et al.
Publicado: (2023)

PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients
por: Huang, Chung-Feng, et al.
Publicado: (2015)

Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients
por: Huang, Jee-Fu, et al.
Publicado: (2015)

Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients
por: Batsaikhan, Batbold, et al.
Publicado: (2022)

Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients
por: Jang, Tyng-Yuan, et al.
Publicado: (2017)

Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan
por: Lu, Ming-Ying, et al.
Publicado: (2021)

Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma
por: Lin, Ching-Chih, et al.
Publicado: (2021)

Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison
por: Chen, Chun-Ting, et al.
Publicado: (2022)

Lower protein expression levels of MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection
por: Huang, Chung-Feng, et al.
Publicado: (2018)

High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study
por: Yu, Ming-Lung, et al.
Publicado: (2005)

Itemization difference of patient-reported outcome in patients with chronic liver disease
por: Lin, Ming-Chieh, et al.
Publicado: (2022)

Baseline Circulating miR-125b Levels Predict a High FIB-4 Index Score in Chronic Hepatitis B Patients after Nucleos(t)ide Analog Treatment
por: Wu, Jyun-Yi, et al.
Publicado: (2022)

Scaling up the in-hospital hepatitis C virus care cascade in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021)

Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients
por: Huang, Jee-Fu, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_38jl00n6seir1jfmjmqdvriq89